CNS Pharmaceuticals has successfully acquired Orphan Drug Designation from Cortice Biosciences for TPI 287, a novel abeotaxane with potential to cross the blood-brain barrier for treating brain tumors.
CNS Pharmaceuticals' Berubicin failed to demonstrate statistically significant superiority in overall survival compared to Lomustine in recurrent glioblastoma patients, but showed comparable clinical outcomes across multiple endpoints.
DelveInsight's latest report reveals a robust pipeline with over 80 companies developing 100+ drug candidates for head and neck cancer, highlighting significant research momentum in this therapeutic area.
BioNTech is progressing BNT327/PM8002, a bispecific antibody, into global clinical trials for first-line small cell lung cancer and non-small cell lung cancer.
CNS Pharmaceuticals presented updated results from its pivotal study comparing Berubicin to Lomustine in recurrent glioblastoma (GBM) patients, showing comparable demographics between treatment arms.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.